AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
520.83B
Market cap520.83B
Price-Earnings ratio
50.78
Price-Earnings ratio50.78
Dividend yield
2.35%
Dividend yield2.35%
Average volume
5.64M
Average volume5.64M
High today
$301.18
High today$301.18
Low today
$293.97
Low today$293.97
Open price
$299.98
Open price$299.98
Volume
4.70M
Volume4.70M
52 Week high
$302.93
52 Week high$302.93
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

AbbVie(ABBV) stock is priced at $294.21, giving the company a market capitalization of 520.83B. It carries a P/E multiple of 50.78 and pays a dividend yield of 2.35%.

As of 2026-11-16, AbbVie(ABBV) stock has fluctuated between $293.97 and $301.18. The current price stands at $294.21, placing the stock +0.1% above today's low and -2.3% off the high.

The AbbVie(ABBV)'s current trading volume is 4.7M, compared to an average daily volume of 5.64M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.

ABBV News

TipRanks 3h
AbbVie put volume heavy and directionally bearish

Bearish flow noted in AbbVie (ABBV) with 7,538 puts trading, or 1.5x expected. Most active are 11/27 weekly 287.5 puts and Jun-27 195 puts, with total volume in...

Simply Wall St 4h
Is AbbVie Undervalued On Its Humira Transition And Board Change?

Board change and new partnerships put AbbVie in focus AbbVie (ABBV) moved into the spotlight after director Jennifer L. Davis resigned from its board following...

Is AbbVie Undervalued On Its Humira Transition And Board Change?
Reuters 10h
Summit shares drop after US FDA declines to approve lung cancer drug - Reuters

...

Summit shares drop after US FDA declines to approve lung cancer drug - Reuters

Analyst ratings

77%

of 30 ratings
Buy
76.7%
Hold
20%
Sell
3.3%

More ABBV News

TipRanks 11h
AbbVie price target raised to $335 from $325 at Barclays

Barclays raised the firm’s price target on AbbVie (ABBV) to $335 from $325 and keeps an Overweight rating on the shares post the Q3 report. In the current envir...

24/7 Wall St. 1d
How Retirees Can Turn $175,000 Into Passive Income With These 4 Dividend Stocks

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

How Retirees Can Turn $175,000 Into Passive Income With These 4 Dividend Stocks
TipRanks 2d
REGENXBIO Earnings Call Signals Progress Toward Gene Therapy Launch

RegenXBio Inc. ((RGNX)) has held its Q3 earnings call. Read on for the main highlights of the call. REGENXBIO’s earnings call carried a strongly optimistic ton...

The Motley Fool 3d
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

Pfizer (PFE +0.21%) and AbbVie (ABBV +0.20%) rank among the biggest drugmakers in the world. Both pharma stocks have also been favorites for many income investo...

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Simply Wall St 3d
What Does AbbVie Gain From Progress In Its Migraine Pipeline Deal?

AbbVie (NYSE: ABBV) partner Brise Pharmaceuticals reported progress on two preclinical migraine programs under their exclusive license agreement. Brise confirm...

What Does AbbVie Gain From Progress In Its Migraine Pipeline Deal?
TipRanks 4d
AbbVie Crohn’s Disease Study Update Offers Limited Near-Term Stock Impact

Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study, “A Post-marketing Non-interventional Study for Upad...

Zacks 4d
The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira

Chicago, IL – November 12, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the...

The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.